利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

18 条记录 (耗时 0.05 秒)

    Selective NPY (Y5) antagonists
    6.
    发明申请
    Selective NPY (Y5) antagonists 失效
    选择性NPY（Y5）拮抗剂

    公开(公告)号：US20050137240A1

    公开(公告)日：2005-06-23

    申请号：US11040328

    申请日：2005-01-20

    申请人： Mohammad Marzabadi ,  Wai Wong ,  Stewart Noble ,  Peter Buhlmayer ,  Heinrich Rueger ,  Yasuchika Yamaguchi ,  Walter Schilling

    发明人： Mohammad Marzabadi ,  Wai Wong ,  Stewart Noble ,  Peter Buhlmayer ,  Heinrich Rueger ,  Yasuchika Yamaguchi ,  Walter Schilling

    IPC分类号： C07D277/42 ,  C07D277/60 ,  C07D417/12 ,  C07D513/04 ,  A61K31/426 ,  C07D277/38

    CPC分类号： C07D277/60 ,  C07D277/42 ,  C07D417/12 ,  C07D513/04

    摘要： This invention is directed to bicyclic and tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. The invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

    摘要翻译： 本发明涉及作为NPY（Y5）受体的选择性拮抗剂的双环和三环化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物和药学上可接受的载体组合而制备的药物组合物。 本发明提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了本发明化合物用于制备用于治疗异常的药物组合物的用途，其中所述异常通过降低人Y5受体的活性而减轻。

    Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands
    7.
    发明申请
    Heteroaryl fused pyridines, pyrazines and pyrimidines as CRF1 receptor ligands 审中-公开
    杂芳基稠合吡啶，吡嗪和嘧啶作为CRF1受体配体

    公开(公告)号：US20060199823A1

    公开(公告)日：2006-09-07

    申请号：US11389646

    申请日：2006-03-24

    申请人： Ping Ge ,  Raymond Horvath ,  Lu Zhang ,  Yasuchika Yamaguchi ,  Bernd Kaiser ,  Xuechun Zhang ,  Suoming Zhang ,  He Zhao

    发明人： Ping Ge ,  Raymond Horvath ,  Lu Zhang ,  Yasuchika Yamaguchi ,  Bernd Kaiser ,  Xuechun Zhang ,  Suoming Zhang ,  He Zhao

    IPC分类号： A61K31/498 ,  C07D487/02

    CPC分类号： C07D471/04 ,  C07D487/04

    摘要： Substituted heteroaryl fused pyridine, pyrazine, and pyrimidine compounds that act as selective modulators of CRF 1 receptors are provided. These compounds are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

    摘要翻译： 提供了作为CRF 1受体的选择性调节剂的取代的杂芳基稠合的吡啶，吡嗪和嘧啶化合物。 这些化合物可用于治疗许多中枢神经系统和周围疾病，特别是压力，焦虑，抑郁，心血管疾病和进食障碍。 还提供了治疗这种疾病以及包装的药物组合物的方法。 本发明的化合物也可用作CRF受体定位的探针，并且作为用于CRF受体结合的测定中的标准物。 给出了在受体定位研究中使用化合物的方法。

    Selective NPY (Y5) antagonists (bicyclics)
    8.
    发明授权
    Selective NPY (Y5) antagonists (bicyclics) 有权
    选择性NPY（Y5）拮抗剂（双环）

    公开(公告)号：US06214853B1

    公开(公告)日：2001-04-10

    申请号：US09343633

    申请日：1999-06-30

    申请人： Mohammad R. Marzabadi ,  Wai C. Wong ,  Yasuchika Yamaguchi ,  Stewart A. Noble

    发明人： Mohammad R. Marzabadi ,  Wai C. Wong ,  Yasuchika Yamaguchi ,  Stewart A. Noble

    IPC分类号： A01K31427

    CPC分类号： C07D277/60 ,  C07D277/42 ,  C07D417/12 ,  C07D513/04

    摘要： This invention is directed to bicyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of the compound of this invention and a pharmaceutically acceptable carrier. This invention further provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of the compound of the invention and a pharmaceutically acceptable carrier.

    摘要翻译： 本发明涉及作为NPY（Y5）受体的选择性拮抗剂的双环化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物与药学上可接受的载体组合而成的药物组合物。 本发明还提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。

    Selective NPY (Y5) antagonists
    9.
    发明授权
    Selective NPY (Y5) antagonists 失效
    选择性NPY（Y5）拮抗剂

    公开(公告)号：US07273880B2

    公开(公告)日：2007-09-25

    申请号：US11040328

    申请日：2005-01-20

    申请人： Mohammad R. Marzabadi ,  Wai C. Wong ,  Stewart A. Noble ,  Yasuchika Yamaguchi

    发明人： Mohammad R. Marzabadi ,  Wai C. Wong ,  Stewart A. Noble ,  Yasuchika Yamaguchi

    IPC分类号： A61K31/426

    CPC分类号： C07D277/60 ,  C07D277/42 ,  C07D417/12 ,  C07D513/04

    摘要： This invention is directed to bicyclic and tricyclic compounds which are selective antagonists for NPY (Y5) receptors. The invention provides a pharmaceutical composition comprising a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention provides a pharmaceutical composition made by combining a therapeutically effective amount of a compound of this invention and a pharmaceutically acceptable carrier. The invention provides a process for making a pharmaceutical composition comprising combining a therapeutically effective amount of a compound of the invention and a pharmaceutically acceptable carrier. This invention further provides the use of a compound of the invention for the preparation of a pharmaceutical composition for treating an abnormality, wherein the abnormality is alleviated by decreasing the activity of a human Y5 receptor.

    摘要翻译： 本发明涉及作为NPY（Y5）受体的选择性拮抗剂的双环和三环化合物。 本发明提供了包含治疗有效量的本发明化合物和药学上可接受的载体的药物组合物。 本发明提供通过将治疗有效量的本发明化合物和药学上可接受的载体组合而制备的药物组合物。 本发明提供了制备药物组合物的方法，其包括将治疗有效量的本发明化合物和药学上可接受的载体组合。 本发明还提供了本发明化合物用于制备用于治疗异常的药物组合物的用途，其中所述异常通过降低人Y5受体的活性而减轻。